Product Information
Registration Status: ActiveSIN00968P
MEDOMYCIN CAPSULE 100mg is approved to be sold in Singapore with effective from 1988-10-05. It is marketed by MEDOCHEMIE SINGAPORE PTE LTD, with the registration number of SIN00968P.
This product contains Doxycycline 100mg in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by MEDOCHEMIE LTD - Factory AZ in CYPRUS.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum).
Indication
Doxycycline is indicated for use in respiratory tract infections caused by Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Legionella spp., or Klebsiella spp. It is also used for prophylaxis of malaria. Doxycycline is indicated for a variety of bacterial infections, from Mycobacterium fortuitum and M. marinum, to susceptible E. coli and Brucella spp. It can be used as an alternative to treating plague, tetanus, Campylobacter fetus
Mechanism of Action
Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis. Doxycycline prevents the normal function of the apicoplast of Plasmodium falciparum, a malaria causing organism.
Pharmacokinetics
- Absorption
- Completely absorbed following oral administration.
- Distribution
- Metabolism
- Hepatic
- Elimination
Toxicity
Symptoms of overdose include anorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia. LD50=262 mg/kg (I.P. in rat).
Active Ingredient/Synonyms
5-hydroxy-α-6-deoxytetracycline | 6-alpha-deoxy-5-oxytetracycline | 6alpha-deoxy-5-oxytetracycline | 6α-deoxy-5-oxytetracycline | Anhydrous doxycycline | Doxiciclina | Doxycyclin | Doxycycline (anhydrous) | Doxycycline anhydrous | Doxycyclinum | Doxycycline |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.